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The current general model of HIV viral entry involves the binding of the trimeric viral envelope glycoprotein gp120/gp41 to cell surface
receptor CD4 and chemokine co-receptor CXCR4 or CCR5, which triggers conformational changes in the envelope proteins. Gp120 then
dissociates from gp41, allowing for the fusion peptide to be inserted into the target membrane and the pre-hairpin configuration of the
ectodomain to form. The C-terminal heptad repeat region and the leucine/isoleucine zipper region then form the thermostable six-helix
coiled-coil, which drives the membrane merger and eventual fusion. This model needs updating, as there has been a wealth of data produced
in the last few years concerning HIV entry, including target cell dependencies, fusion kinetic data, and conformational intermediates. A more
complete model must include the involvement of membrane microdomains, actin polymerization, glycosphingolipids, and possibly CD4 and
chemokine signaling in entry. In addition, kinetic experiments involving the addition of fusion inhibitors have revealed some of the rate-
limiting steps in this process, adding a temporal component to the model. A review of these data that may require an updated version of the
original model is presented here.D 2003 Elsevier B.V. All rights reserved.Keywords: HIV; Fusion; Env; SIV; Virus; CD4; gp120; gp41; CXCR4; CCR5; Six-helix bundle1. Introduction
HIV/SIV deliver their genetic material into the cell by
direct fusion of the viral membrane with the plasma mem-
brane of the host cells [1]. The fusion is mediated by Env
glycoproteins [2–5], which are organized into oligomeric,
probably trimeric spikes [6], and anchored in the viral
membrane by the gp41 transmembrane protein. The Env
glycoprotein, gp120, forms surface trimeric spikes, which
are associated by noncovalent interactions with each subunit
of the trimeric, normally hidden, gp41 [7]. The similarity
between structural motifs of gp120–gp41 and influenza
hemagglutinin (HA) leads to the notion that the native
conformation of gp41 is metastable and it is stabilized by
gp120 [8,9]. The triggering mechanisms that activate Env
are quite complex involving target cell CD4 [10], co-
receptors [11–16], and perhaps other cell surface compo-
nents [17–19]. These interactions trigger a barrage of0005-2736/03/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
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fusion process [20–25] (see Fig. 1). The final outcome of
the reaction is the formation of a six-helix bundled gp41
ectodomain (Fig. 2) core structure consisting of three N
helices paired with three anti-parallel C helices [26–29].
The six-helix bundle structure is (Fig. 2) similar to the
proposed fusogenic structures of envelope fusion proteins
from influenza, Moloney murine leukemia virus, simian
parainfluenza virus 5, Ebola virus, and simian immunode-
ficiency virus, as well as to the snarepin fusion machinery
involved in intracellular fusion events [30]. The formation
of the six-helix bundle presumably occurs concomitantly
with membrane fusion [31]. HIV fusion can be inhibited by
peptides that mimic the sequences of the N- and C-terminal
helices by binding to the N terminal heptad repeat triple
helices, or to the C-terminal regions of Env, thereby pre-
venting six-helix bundle formation [32–34].
The model shown in Fig. 1 is based on structural
information of the gp41 core and on studies with fusion
inhibitors. It has served as a guide to direct our thinking
about the way the envelope glycoprotein mediates mem-
brane fusion. However, some crucial pieces of the puzzle are
missing. For instance, although we know that the first step
Fig. 1. Model of HIV-envelope-mediated membrane fusion according to Chan and Kim [4]. Upon binding to CD4 and co-receptor, gp120 undergoes
conformational changes that allow gp41 fusion peptide insertion into the target membrane and the formation of a pre-hairpin structure. As the gp120 dissociates
from gp41, the latter undergoes a slow reaction, which transforms the pre-hairpin into the six-helix bundle. It is during this process that the envelope-induced
fusion is sensitive to inhibition by C-terminal peptides. (Current data show that Env–CD4 interactions trigger the pre-hairpin state that becomes sensitive to C-
terminal inhibitors and that co-receptor engagement leads to rapid six-helix bundle formation [48]). The formation of the six-helix bundle promotes complete
fusion, in which the fusion peptide and the transmembrane segment of gp41 lie parallel on a contiguous bilayer. Reprinted from Ref. [4], with permission from
Elsevier.
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inhibitors, it has not been shown that the fusion peptide
inserts into the target membrane under these conditions.
Other steps that occur before or after six-helix bundle
formation have not been resolved. These include further
conformational changes in Env, aggregation of viral pro-
teins, lipid-fusion peptide interactions, hemi-fusion, fusion
pore formation, and pore widening.
In order to get a handle on these intermediate processes,
we need to know the rate at which the reaction proceeds.
Therefore, kinetic assays and methodologies have been
developed to dissect intermediate steps in the fusion reac-
tion. In Section 2, we will describe these kinetic approaches.
The role of the target membrane in assembling the receptors
that trigger Env and participate in the formation of fusion
complexes will be discussed in Section 3. Section 4 will
describe various approaches to reveal the temporal sequence
of conformational changes in Env as the fusion reaction
proceeds. The final steps that couple the protein conforma-
tional changes to the lipid rearrangements required for
fusion will be discussed in Section 5.2. Kinetics of the HIV fusion reaction
Fluorescent probes have been extensively used in the
study of viral membrane fusion (for a review, see Ref. [35]).
Studies of fusion of intact virus with cells have utilized
fluorescent dequenching assays, which are based on theredistribution of a lipid dye incorporated into the viral
membrane to the target membrane as a result of fusion.
However, because of the difficulty in purifying HIV virus
into highly active homogenous stock, noninfectious par-
ticles and general debris can lead to nonspecific transfer
and, therefore, a dequenching artifact, which occurs on
roughly the same time scale as HIV fusion. However, a
photosensitized labeling methodology provided a reliable
time course of fusion of HIV and SIV with biological
membranes [36]. The most striking result is that at 37 jC
SIV reaches maximum fusion with a t1/2 of 19 min. This
indicates that the CD4 and co-receptor-induced triggering
events leading to HIV/SIV Env-mediated fusion are sto-
chastic, leading to a much slower fusion kinetics as com-
pared to the low pH fusion induced by influenza HA. The
lack of synchrony in the activation of HIV/SIV Envs
therefore provides an opportunity for the C terminal peptide
inhibitors to bind to the pre-hairpin grooves, which become
transiently exposed following CD4-induced triggering of
HIV-1 Env.
Kinetics of HIV/SIV Env-mediated membrane fusion
have extensively been studied using envelope glycoproteins
expressed in cells interacting with target cells bearing CD4
and appropriate co-receptor [37]. Although there are subtle
differences between fusion of intact virus with cells and
Env-mediated cell–cell fusion, the basic mechanisms that
underpin both phenomena are the same. Although syncytia
counting [38] and gene reporter assays [39] of cell–cell
fusion have been used to monitor HIV Env-mediated fusion,
Fig. 2. Cartoon representations of atomic-scale models of HIV gp41 catalyzing virus/target cell membrane fusion. Two opposing members are shown to
illustrate the likely larger group of proteins radially aligned to form a fusion pore. Helical segments of the proteins are shown as cylinders, and the intervening
segments are shown as alpha-carbon traces. The fusion peptides are colored red, the N- and C-terminal helices of the six-helix bundle are colored yellow and
cyan, respectively, and the anchors in the virus membrane are colored blue. The intervening segments between the fusion peptides and the N-terminal helices
are in orange, between the N- and C-terminal helices in green, and between the C-terminal helices and the viral anchors in magenta. The coordinates for the
residues of the six-helix bundle were obtained from Chan et al. [26] (1AIK.pdb), and for the extension of the N-terminal helices and the loops to the C-terminal
helices were derived from the structure of SIV from Caffrey et al. [29] (2EZO.pdb). (A) Pre-fusion state: Partial incorporation of two of the three C-terminal
helices into the core bundle of three N-terminal helices is presumed to provide the energy for bringing the membrane-embedded fusion peptides and viral
anchors into proximity, thus placing the two membranes into apposition. Having the third C-terminal helix ‘‘unzipped’’ allows for the binding of mimetic
peptides to the bundle, which are known to inhibit the fusion mechanism beyond this stage. The oblique angle of the fusion peptides is presumed to destabilize
the outer, apposed layer of the target cell membrane. (B) Small fusion pore: Incorporation of the final C-terminal helix into the bundle provides the energy to
bring the fusion peptides and viral anchors closer together, thus initiating merging of the outer leaflets and then fusion of the membranes. See text for further
explanation.
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using dye transfer assays [40–44].
Initial fusion events have been detected after a time lag
of 10–15 min following co-culture at 37 jC, which is
believed to be correlated to the binding of gp120 to CD4
receptor [41,45,46]. The observation that the CD4-indepen-
dent mutant 8 [47] displays a reduced time lag as
compared to that of wild-type fusion supports this hypoth-
esis [48]. This lag time can be dramatically shortened for
HIV-1 through pre-incubation at 25 jC, which allows CD4
docking to take place but prevent co-receptor binding [31].
Similar decreases have been found in some systems with
pre-incubation at 31 jC [38]. This binding and engagement
of CD4 represent the first rate-limiting step. This lag is
followed by a relatively quick rise in fusion yield that
saturates at some level (usually after about 50–100
min), creating a curve easily fit to a sigmoidal function
[48].Although it is reasonable to assume that the relative
densities of envelope and receptors will modulate these
curves, it has been observed that envelope densities affect
only the saturation fusion levels and not the rapidity of the
kinetics [44]. The lack of pre-warming cells before fusion,
though, may have altered those observed lag times. It has
also been shown that the rapidity of fusion is greatly
increased by increased co-receptor levels or by an enhanced
envelope affinity for co-receptor [49]. The rapidity of these
kinetics have been shown to correlate well with sensitivity
to fusion inhibitors such as DP178, also known as T20
[48,49], and may account for drug resistance found in
patients receiving this treatment [50]. Thus, in the cascade
of conformational changes that gp120/gp41 goes through,
conformational-dependent epitopes of the proteins are ex-
posed, allowing for windows of opportunity for inhibitors
that bind to these transient epitopes, to adhere and inhibit.
Further examinations of time-dependent changes in gp120/
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Sections 4.1 and 4.2.3. The role of the target membrane in HIV fusion
Although in Fig. 1 only one trimer of Env is depicted as
being triggered to produce a fusion event, it appears that for
this process to take place efficiently, several HIV Env
trimers must interact with host cell receptors, CD4, and
co-receptors, such as CXCR4 or CCR5, that determine the
tropism of different HIV-1 isolates. This process appears to
be highly cooperative and is affected by receptor density as
well as by Env-receptor affinity [51]. It has been estimated
that four to six CCR5 receptors [52] and multiple CD4
receptors [53] are required to form a fusion pore. In primary
CD4+ T cells that typically express fewer than 10,000
CCR5 or CXCR4 molecules and about 65,000 CD4 mole-
cules per cell [54], the cooperativity required for HIV-1
Env-mediated fusion will unlikely be satisfied through
random collisions between the receptors in a fluid mosaic
membrane [55]. The idea that co-receptor clusters large
enough to cooperatively trigger a productive HIV-1 Env-
mediated fusion event are assembled in domains of the
plasma membrane therefore emerged.
In the last decade, the notion of heterogeneity of phases in
the plasma membrane and in particular the presence of
specialized membrane microdomains, or lipid rafts, has been
highlighted [56,57]. Their formation could be driven by a
special interaction between different lipids, such as choles-
terol, sphingomyelin, and glycosphingolipids, which have a
propensity to form, in dynamic equilibrium, a more ordered
domain separate from the more liquid plasma membrane. The
special environment they provide drives an uneven distribu-
tion of proteins on the plasma membrane depending on their
affinity for rafts. The main means of observation of those
domains has so far been isolation by flotation on a sucrose
gradient. Their more ordered organization provides them
with a resistance to solubilization with some nonionic deter-
gents under certain temperatures. Solubilization of the cells
under those conditions allows then their recovery and the
study of their composition. They have been shown to be
enriched in GPI anchored proteins, receptors (EGF, PDGF,
CD4, TCR), and signaling molecules (src, Gproteins, MAPK
kinase, shc, GRB, SOS). Due to the very small size of the rafts
beyond the resolution of fluorescencemicroscopy, labeling of
those proteins reveals an even distribution. However, cross-
linking of those proteins has been shown to result in co-
patching of the small domains to form bigger aggregates that
can be readily observed in the form of a punctuate fluores-
cence. Beyond the advantage of visualization of the rafts, it
provides insights into the dynamic of those domains and their
ability to reorganize in response to a stimulus.
Rafts were shown to serve as entry and exit sites for
microbial pathogens and toxins, such as influenza virus
[58], measles virus [59], and cholera toxin [60]. They alsoappear to play a role at various stages of HIV-1 replication
cycle such as virion packaging [61], assembly and budding
from infected cells [62–64], and viral entry [18,65]. A way
to test the involvement of rafts is to alter their formation.
Methyl beta cyclodextrin (MhCD) has a high affinity for
cholesterol, a main constituent of rafts. Treatment of cells
with this drug in appropriate conditions removed enough
cholesterol from the plasma membrane to disrupt the rafts.
Such a treatment did inhibit the infectivity of HIV-1 leaving
the infectivity of other viruses such as VSV unaffected [66].
In addition, replenishment of depleted cells with cholesterol
did restore the HIV-1 Env-mediated entry, indicating that the
cells were not permanently damaged by their treatment with
MhCD. Furthermore, it has been recently shown [67] that
MhCD treatment did not alter the HIV-1 permissivity of
cells expressing high level of receptors but selectively
inhibited fusion of cells expressing lower levels of recep-
tors. This indicates that the cells depleted of cholesterol are
not drastically damaged and that cholesterol per se is not
necessary for the fusion to proceed but that the raft organi-
zation seems crucial for HIV-1 entry in cells expressing low
levels of receptors, probably through their concentration in
distinct domains.
If CD4 is considerably enriched in rafts [68,69], CCR5 is
enriched to a lesser extent [65,66] and CXCR4 is poorly
enriched [66,67] if at all [70]. Along with this notion,
immuno-precipitation experiments [71–73] showed consti-
tutive association of CD4 with CCR5 but very weak
association with CXCR4. The rafts do not seem therefore
to naturally contain sufficient clustering of co-receptor and
CD4. Indeed, using fluorescence microscopy, a number of
groups have found CD4 and co-receptors to be randomly
distributed on the surface in an unstimulated state [74]. Rafts
have, however, the faculty to reorganize upon stimulation.
Following association of virus or gp120, co-localization of
these molecules has been detected by fluorescence micros-
copy [74] and an increase of the presence of CXCR4 in raft
seen in sucrose density gradient. According to other reports
[70], this phenomenon is not observed, which raises interest
in the dynamics and the time frame of this reorganization.
The nature of this reorganization that would allow the
formation of clusters large enough to support the coopera-
tivity of HIV-1 Env-mediated entry is not well understood. It
seems, however, that the formation of the fusion complex, at
least in cells expressing low levels of receptors [67],
requires cholesterol [65] and a functional actin [74]. Inter-
estingly, some reports also showed that tyrosine kinase
inhibitors could inhibit the syncytia formation induced by
different X4 tropic strains in various cell lines [75].
The reorganization of the rafts can be mediated by the
binding of a ‘‘raft’’ protein [76] or by a protein that would
change its affinity for rafts upon binding [77]. As mentioned
earlier, rafts are particularly enriched in signaling molecules,
most notably members of the Src-tyrosine kinase family.
The raft aggregation can therefore provide a favorable
environment for signal transduction to proceed. Raft clus-
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phosphorylation and actin in those domains [76]. It seems
therefore that actin and signaling (notably tyrosine kinase)
may participate in the formation and/or the stabilization of a
bigger complex [76,78]. CD4 being the receptor of HIV and
present in rafts is of particular interest. Taking CD4 out of
rafts, either by depleting the cells of cholesterol or more
elegantly by mutating it so that it would still bind to gp120
but not partition in the rafts [79], inhibited the co localiza-
tion of CD4 and co-receptors upon treatment with gp120
and, therefore, HIV-1 fusion. The localization of CD4 in
rafts seems to be important for the fusion process although
this idea is still controversial [79a]. In lymphocytes, CD4
cross-linking has been shown to induce tyrosine kinase
activation and simultaneous association of p56Lck with
cytoskeleton [80]. Interestingly, it was also shown that
expression of p56Lck retards the internalization of CD4
and increases its ability to form syncytia [75]. P56 anchors
CD4 to microvilli [81], which have been shown to be the
site of localization of clusters of CD4 and co-receptors [82].
Those membrane protrusions rich in actin and cholesterol-
based domains may provide a possible site for fusion [67].
Where and how large clusters could be formed, allowing
HIV-1 Env-mediated fusion to proceed, is still poorly
understood. The requirement of rafts, intact actin, and
signaling in the formation of syncytia suggests that the
process would involve the clustering of domains promoted
by actin and signaling processes. CD4 is localized in rafts
and could facilitate this clustering upon gp120 binding, but
how this relates to the mechanism of co-receptor recruitment
and what role co-receptor engagement and signaling might
play, even though co-receptors are not regularly localized in
rafts, is currently poorly understood. Gp120 has notably
been shown to have signaling capabilities on both CD4 and
co-receptors separately [83,84]. Some experiments have
shown that mutations made in CD4 and/or CCR5 affecting
their signaling capacities do not have an effect on HIV-1
entry [85]. However, Pertussis toxin has been shown to
deactivate CCR5 and, in some cases, to block the entry of
R5 utilizing strains [86]. Clearly, CD4 signaling alone
cannot support fusion, as supported by experiments in
which CD4 independent strains efficiently recruit co-recep-
tors to allow their entry [87]. The active participation of
CD4, co-receptors, and other possible participants such as
glycosphingolipids, possibly through signaling and actin
rearrangement of rafts to form clusters large enough to
support HIV entry, needs to be further characterized.4. Conformational intermediates
4.1. CD4 and co-receptor-induced conformational changes
in HIV Env revealed by Mabs
In order to study the initial interaction between HIV and
target cells, a soluble form of CD4 (sCD4) has beenemployed as a receptor mimic in the analysis of the
gp120–CD4 fusion intermediate [88]. CD4 binds in a
recessed cavity on gp120 and this high affinity interaction
forms a gp120–CD4 complex for which structural informa-
tion is available [89]. As this is the sole conformation of
gp120 for which the X-ray crystal structure is known, our
understanding of receptor-induced conformational changes
remains incomplete. Co-receptor engagement is generally
thought to induce further conformational changes in the
envelope complex facilitating gp41 fusogenic activity. Al-
though the Env conformational changes leading to fusion
are depicted in Fig. 1 as resulting from concerted Env-
CD4–co-receptor interactions, it appears that these changes
are due to sequential contacts as discussed in detail below.
4.1.1. Conformational changes in gp120 due to CD4
engagement
In the absence of complete structural information, con-
formational changes in gp120 during receptor engagement
have been inferred from immunochemical, biochemical, and
mutagenic analysis. Upon engagement, sCD4 induces well-
documented conformational changes in the envelope pro-
tein, the most dramatic of which results in the dissociation
of gp120 from gp41 under specific assay conditions [88].
Such dissociation occurs more readily for X4 tropic viruses
than for R5 tropic, probably reflecting subtle alterations in
the oligomeric envelope structures [90,91]. This event has
been proposed to trigger the fusogenic potential of gp41 [9],
presumably by releasing steric constraints and allowing
gp41 to transition from a metastable conformation into a
highly stable ‘‘six-helix bundle’’ [26–29].
Analysis of sCD4-induced conformational changes in
gp120 rapidly identified structural changes that permit co-
receptor interactions and subsequent viral entry. The gp120
V3 loop was initially identified as the principal determinant
of co-receptor specificity [92]. Structural changes in the V3
loop occur following CD4 binding and are detected due to
altered proteolytic sensitivity and antigenic profile [93].
Shortly thereafter, the contribution of other conserved
gp120 structures was realized. One of the most well-studied
conformational changes following sCD4 engagement of
gp120 is the exposure of conserved, discontinuous epitopes,
which are recognized by the human antibodies, 17b, 48D,
and the murine monoclonal antibody CG10 [94–96]. These
epitopes are located near or within the bridging sheet and
the V3 loop on gp120 [89]. CD4 binding has been impli-
cated in moving the V2 loop [95] and promoting the
exposure and/or stabilization of the bridging sheet [89],
thus facilitating the binding of antibodies to these epitopes.
Although sCD4 binding to soluble gp120 [94] or HIV-
infected cells [95] readily induces conformational changes
permitting reactivity with the co-receptor binding site anti-
bodies, analyses in viral–cell and cell–cell fusion systems
[97–99] indicate that the co-receptor-binding domain
remains largely occluded during viral entry. In agreement,
no enhanced reactivity is observed with co-receptor binding
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either in the presence or absence of co-receptor expression
[97]. Collectively, these studies suggest that the close
physical proximity of fusing membranes, rather than co-
receptor interactions impedes detection of this conforma-
tional change.
Although co-receptor binding site antibodies fail to
neutralize fusion, these antibodies can potently block
sCD4-activated fusion with target cells expressing co-re-
ceptor alone [98]. These findings confirm that membrane-
anchored envelope is primed by CD4 to promote interac-
tions with co-receptor, similar to conclusions that have been
reached based on analysis with soluble molecules [92,100].
In contrast to that shown in Fig. 1, these studies support a
two-step model for receptor engagement that involves initial
interactions between gp120 and CD4, followed by confor-
mational changes that permit interaction of the gp120–CD4
complex with co-receptor.
Additional regions of gp120 also undergo conformation-
al changes due to CD4 binding. These epitopes are located
in the C1–C4/C5 region of gp120, which is implicated in
gp41 interactions [101]. When soluble gp120 is incubated
with sCD4, these conformational changes are readily
detected. However, following the engagement of envelope
expressing cells with sCD4, these interface epitopes remain
occluded due to gp41 interactions. Likewise, during cell–
cell fusion, these epitopes do not become exposed following
CD4 binding. Instead, they become accessible to antibody
binding following dissociation of gp120 from gp41, which
is dependent on co-receptor interaction [97].
4.1.2. Conformational changes in gp41 due to CD4
engagement
In addition to triggering conformational changes in
gp120, CD4 binding also promotes conformational changes
in gp41. As for gp120, investigating the antigenicity of gp41
before and after sCD4 engagement has provided important
structural information. Two regions of gp41 have been
found to be particularly immunogenic in vivo. One of these
regions spans amino acid residues 598–604 and includes a
nonhelical hydrophilic region that forms a disulfide loop in
the six-helix bundle. The other region includes residues
644–663 and comprises a portion of the C terminal a-helix.
In the absence of sCD4 binding, antibodies to these epitope
clusters react minimally with infected cells. Following sCD4
binding, a substantial increase in immuno-reactivity is
observed probably reflecting conformational changes in
gp41 [102]. Alternatively, such immuno-reactivity could
be due in part to conformational changes in gp120 resulting
in unmasking gp41 epitopes or additionally due to dissoci-
ation of gp120 from gp41. However, increased reactivity
has been observed in the absence of gp120 dissociation
[102], indicating that subunit dissociation is not absolutely
required for these CD4 induced conformational changes.
A monoclonal antibody designated NC1, generated
against the core of fusion active gp41, also reacts withHIV-infected cells following sCD4 engagement [103]. Re-
activity with NC1 shows less than a two-fold enhancement
following sCD4 binding and due to the assay conditions
may in part reflect gp120 shedding [104]. Whether gp41
undergoes CD4-induced conformational changes permitting
reactivity with NC1 in the absence of gp120 dissociation
remains speculative. Due to the specificity of NC1, these
conformational changes would likely reflect formation of
the six-helix bundle conformation. Recently, enhanced NC1
reactivity has been observed following interactions between
HIV-1 Env-expressing cells and susceptible target cells (A.
Dimitrov et al., in preparation).
Contrasting results are observed with a disparate gp41
monoclonal antibody, 2F5, which reacts with a continuous
epitope (a.a. 656–671) proximal to the transmembrane
domain of gp41. The 2F5 epitope is strongly exposed on
the surface of infected cells [102,103,105], and interestingly,
sCD4 binding promotes a decrease in immuno-reactivity
[102]. This decrease may reflect the resolution of gp41 into
a stable six-helix bundle following gp120 dissociation, as
the 2F5 epitope is occluded once N and C helices interact to
form six-helix bundles. However, a slight decrease in 2F5
signal (1.3-fold) is seen following sCD4 incubation with
HIV-infected cells under conditions where shedding would
not be appreciable [102]. As for NC1, such altered immuno-
reactivity may reflect six-helix bundle formation, but as yet
it remains unclear whether CD4 engagement can promote
such conformational changes.
In agreement with observations from sCD4 experiments,
conformational changes in gp41 have been observed using
membrane-bound CD4 [102]. Early analysis employed an
immunochemical approach to investigate the exposure of
immuno-dominant gp41 epitopes at the interface of HIV
infected and target cells. Staining with gp41 antibodies
reveals that previously cryptic gp41 epitopes become ex-
posed at the fusion interface. Recent analysis of temporal
gp41 conformational changes also demonstrates selective
gp41 reactivity at the interface of attached Env and target
cells [105]. Gp41 conformational changes, as detected by
antibody binding, occurs rapidly upon interaction of Env
and target cells and remains localized to the cell–cell
interface until the initiation of fusion. The kinetics of
epitope exposure, combined with the localized immuno-
reactive pattern and the sensitivity of short-term co-cultures
to T20, lead to the hypothesis that the immuno-reactive
gp41 antigen is reflecting exposure of the gp41 pre-hairpin
fusion intermediate. In this study, it appears that CD4
engagement is sufficient to induce the exposure of this
intermediate as similar gp41 immuno-reactivity is observed
in the absence of co-receptor.
Numerous studies have noted the accessibility of the 2F5
epitope on envelope expressing cells [102,103,105]. Upon
sCD4-envelope engagement, 2F5 demonstrates decreased
immuno-reactivity [102], but during the co-culture of Env
and target cells, reactivity with 2F5 remains unaltered. This
discrepancy may reflect differences in assay sensitivity or
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ences of soluble versus cell-surface CD4.
4.1.3. Co-receptor-induced conformational changes
For the last two decades, it has been appreciated that
conformational changes elicited upon CD4 engagement are
not sufficient to permit fusion. This has led to the hypothesis
that co-receptor engagement induces further conformational
changes in the envelope–CD4 complex, culminating in
activation of gp41. If the CD4-induced conformational
changes in gp41 reflect exposure of the pre-hairpin inter-
mediate as has been hypothesized, then what is the role of
co-receptor in inducing further conformational changes? To
address this question, the effect of co-receptor engagement
on envelope conformation has been investigated by probing
for altered immuno-reactivity. During cell–cell fusion, the
exposure of epitopes that are located at the gp120–gp41
interface occurs immediately preceding fusion. Reactivity
with antibodies to these epitopes is observed as a discrete
signal at the interface of Env and target cells and is not
observed in the absence of co-receptor. Hence, co-receptor
engagement is implicated in facilitating dissociation of
gp120 from gp41 and permitting antibody reactivity [97].
Conformational changes in gp41 have also been investi-
gated using a gp41 peptide inhibitor called DP178, also
known as T20. T20 was fortuitously discovered to inhibit
HIV entry and most likely targets a gp41 ‘‘pre-hairpin
intermediate’’ [106] that is characterized as having exposed
N and C helices. Furuta et al. [34] probed conformational
changes in gp41 by determining the ability of epitope-
tagged T20 to immuno-precipitate intermediate gp41 struc-
tures under a variety of assay conditions. It appears that for
some strains of HIV, sCD4 or membrane-anchored CD4 is
sufficient for exposing the pre-hairpin intermediate while for
other HIV isolates, co-receptor engagement is clearly a
prerequisite. Presumably, in the latter case, both co-receptor
and CD4 are required to drive pre-hairpin formation. Other
studies using gp41-derived peptides suggest that the pre-
hairpin structure appears at some point after the gp120–
CD4 complex forms, and persists during a fusion lag phase
that precedes lipid mixing [31,48,105] and then disappears
concomitant with co-receptor engagement (see below).
Because both CD4 and co-receptor are necessary for six-
helix bundle formation, it would be interesting to see the
time course of gp41 capture by T20 following interactions
between Env and CD4 and/or co-receptors. Collectively,
these studies highlight the advances in our understanding of
receptor-induced conformational changes, for both gp120
and gp41, and illustrate the complexities in understanding
receptor-induced conformational changes for HIV.
4.2. Kinetic studies with entry inhibitors
Studies using inhibitors to arrest fusion intermediates
provide important insights into the sequential nature of
receptor induced conformational changes. The inhibitoryeffects of anti-CD4 antibodies (e.g. Leu3A and Q4120) that
block gp120-CD4 binding, chemokine receptor antagonists
(e.g. AMD3100, TAK779) that block gp120-co-receptor
binding, peptide inhibitors of six-helix bundle formation
(e.g. T20, C34), and anti-six-helix bundle antibodies can be
studied as a function of their time of addition [38,42,48].
HIV-1 Env-mediated fusion is completely inhibited when
Leu3A, C34, or AMD3100 is added to the fusion reaction
mixture during the first 10–15 min of co-culture. Leu3A
added at later time points has a lowered inhibitory effect that
rapidly is reduced to zero, while inhibition by AMD and
C34 is still at about 50% of control. In the case of HIV-1
Env-mediated fusion, a considerable length of time was
found between the fall of Leu3A inhibition and AMD3100
inhibition, suggesting a time scale of tens of minutes
between CD4 binding and CXCR4 engagement [48]. In
the case of HIV-2 Env-mediated fusion, this window of time
is considerably reduced (S.A. Gallo and R. Blumenthal, in
preparation). This delay is also found in the formation of the
six-helix bundle, through the use of C34 and T20 [42].
Fusion levels as a function of time of addition of C34 and
AMD3100 have been found to be equivalent, indicating that
engagement of gp120 by CXCR4 and formation of six-helix
bundles follow similar kinetics and that once CD4 binding
has occurred, the engagement of co-receptor is the rate-
limiting step. The model shown in Fig. 1 needs to be re-
assessed in regard to these data showing that Env-CD4
interactions trigger the pre-hairpin state that becomes sen-
sitive to C-terminal inhibitors and that co-receptor engage-
ment leads to rapid six-helix bundle formation.
The evolution of six-helix bundle formation has been
measured in a similar fashion by adding a rabbit anti-six-
helix bundle antibody at different times after co-culture after
first priming cells with a 2 h incubation at 31 jC [38]. It was
found that selected populations of cells which have already
bound to CD4 need about 30 min to form six-helix bundles,
which is consistent with the above finding, assuming six-
helix bundle and co-receptor engagement happen concom-
itantly. This assumption has been shown to be valid not only
through kinetic measurements (as above), but through the
sensitivity of the reversibly temperature arrested fusion state
(TAS) to peptide inhibition. Target and effector cells incu-
bated at 25 jC experience arrested fusion at the point of
CD4 binding, but before co-receptor engagement, as
evidenced by the inability of sCD4 (added at the end of
TAS) to inhibit fusion while CXCR4 binding peptide, T22,
was still able to inhibit. Release from this state through
elevated temperatures to 37 jC promotes fusion with a
marked increase in kinetics above that of fusion without
TAS pre-incubation. Addition of T20 during TAS allows for
inhibition of fusion while T20 addition at the time of release
from this arrested state yields ineffectual inhibition, indicat-
ing that six-helix bundle formation occurs quickly after co-
receptor binding [31].
The addition of steroyl lyso-phosphatidyl choline (Lyso-
PC) can also reversibly arrest fusion, but at the point of
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ture [107] (see below). Thus, Lyso-PC arrested state (LAS)
represents a stage in the fusion cascade that is further
evolved than that of TAS. If T20 is added at LAS with
subsequent washing, fusion is inhibited, indicating that the
six-helix bundle has not yet formed [31]. This supports the
hypothesis that the transition to bundle formation occurs
concomitantly with fusion, inducing pore formation and
expansion. An alternative hypothesis is that the six-helix
bundle forms before membrane merger and the higher-order
clustering of these bundles provides the final driving force
for fusion. This is supported by the positive staining of
effector/target cell contacts arrested at 32 jC by anti-six-
helix bundle antibodies [38]. It is also possible that T20 can
interfere with fusion at an incomplete stage of six-helix
bundle formation (see Fig. 2).
All of this kinetic information is important in dissecting
HIV entry and especially in determining which steps are rate
limiting. For instance, it seems a great deal of time is spent
between CD4 binding and co-receptor binding. This may be
due to a requirement of multiple co-receptors acting in
concert. HIV fusion is likely to be a slow, stochastic
process, and its rate is clearly dependent on the density of
the involved molecules. Thus, there may be a need for the
spatial recruitment of several CXCR4 molecules to be in
close proximity to each other and to CD4. This is in
agreement with the raft dependence of fusion as described
in Section 3. This co-localization of receptors and subse-
quent interaction with envelope maybe a bottleneck in the
fusion process and may represent a new area for drug
development.
Along these lines, it may be quite important to determine
the windows of opportunity with which fusion is sensitive to
different inhibitors. T20 inhibition is greatly enhanced when
added during TAS, as well as when it is pre-incubated with
sCD4, indicating that fusion becomes sensitive to T20 as
early as CD4 engagement. It has also been clearly shown
that the rapidity of fusion greatly affects the inhibitory
ability of anti-viral peptides and chemokine agonists [48].
Fusion kinetics can be modulated by changing target cell co-
receptor levels or by using envelope glycoproteins with
different co-receptor affinities [49]. Increased receptor den-
sity or enhanced envelope affinity for co-receptor increases
the chance of triggering the CD4 engaged envelope and
therefore increases the rate of transformation of the gp41
ectodomain from the pre-coiled-coil state to six-helix bun-
dle, decreasing the window of sensitivity to T20 [49]. Thus,
kinetic data may have great relevance to disease manage-
ment, as well as to the elucidation of the mechanism of viral
entry.
4.3. Fusion peptide insertion
According to the model shown in Fig. 1, the gp41 fusion
peptide inserts into the target membrane in the pre-hairpin
state. However, no evidence is available for this state in thecase of HIV/SIV Env-mediated fusion. The model is based
on analogies with influenza HA-mediated fusion. In the case
of HA-mediated fusion, two lines of evidence suggest
fusion peptide insertion prior to fusion: (1) By lowering
the temperature, a long-lived, low-pH HA fusion interme-
diate has been identified that is committed to fusion [108].
Following a temperature jump to 37 jC at neutral pH, this
intermediate proceeds to fusion at a similar rate and extent
as that seen for low-pH fusion. The committed state is
insensitive to treatments with trypsin or DTT, which release
HA1, but is reversed by treatment with proteinase K and
thermolysin, which affect HA2. The committed state thus
represents interactions between HA2, presumably including
the fusion peptide, and the target membrane. (2) Photo-
labeling studies of the interactions between intact influenza
virus with liposomes demonstrated insertion of HA2 into the
target membrane as a kinetically distinct step prior to the
actual fusion of the viral and target membranes [109–111].
Using energy transfer from a membrane-incorporated fluo-
rophore to activate [125I]iodonaphthylazide label, photolab-
eling of HA was also demonstrated using biological
membranes as targets [112]. Durrer et al. [113] confirmed
that it is only the N-terminal fusion peptide part of HA2
(residues 1 to >22) in those systems that become labeled.
However, under conditions of HA inactivation, the fusion
peptides were found to insert back into the viral membranes
(which also contain the C-terminal, transmembrane anchors)
[114,115].
Attempts have been made to determine whether HIV/SIV
Env inserts into target membranes in the pre-fusion state by
photosensitized labeling [36]. Although incubation of HIV
Env-expressing cells with target cells at 23 jC does not lead
to fusion, the gp41 in this ‘‘temperature-arrested state’’ is
sensitive to the C terminal peptides, indicating that the N-
terminal triple-stranded coiled coil is accessible under these
conditions [31,48]. By measuring incorporation of
[125I]INA into both HLA DR and HIV/SIV Env (both
present in membranes of Env expressing cells but not in
target cells), upon interaction with fluorescently labeled
target cells, it is possible to examine whether gp41/gp32
insertion into the target membrane takes place prior to actual
fusion. If this was the case, preferential labeling of gp32/
gp41 (i.e. its fusion peptide) over HLA DR, whose trans-
membrane anchor will only be labeled under conditions of
actual fusion, will occur. No preferential labeling of gp32
was seen at 23 jC [36], indicating that no fusion peptide
insertion takes place under these conditions. However, the
assay might not be sufficiently sensitive to measure inser-
tion prior to fusion.
Insertion of the HIV fusion peptide into viral membranes
is suggested by experiments showing perturbation of these
membranes when CD4 and co-receptor-associated beads
were added to cells expressing the HIV-1 envelope glyco-
protein [116]. The CD4 and co-receptor-induced permeabi-
lization of Env-expressing cells occurred with the same
specificity with respect to co-receptor usage as cell fusion.
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nal gp41 peptide inhibitors of HIV-1 fusion blocked this
effect. A similar membrane destabilization of Env-express-
ing cells was seen when incubated with target cells at a ratio
of target cell/Env-expressing cell z 5:1. However, no de-
stabilization of target cell membranes was observed when
incubated at an Env-expressing cell/target cell ratio z 5:1.
Incubation at a target cell/Env-expressing cell ratio c 1:1
resulted in cell–cell fusion without leakage. Therefore, it
appears that relocation of the fusion peptide following the
CD4 and co-receptor-induced conformational changes in
Env initiates destabilization of the Env-expressing cell
membrane rather than the target membrane bilayer.
Experiments with mutant HIV-1 Envs indicate that the
fusion peptide is indeed responsible for this effect. Substi-
tution of Val residue at position 2 of gp41 fusion peptide
with Glu [117] resulted in no leakage. By contrast, Envs
with an unmodified fusion peptide but with a deletion of the
sequence D665–682 in the membrane-proximal domain
[118] (see below) were perfectly leakage-competent (A.S.
Dimitrov and R. Blumenthal, in preparation). Both mutant
Envs did not mediate cell fusion. The observation that the
D665–683 Env self-inserts its fusion peptide but does not
cause fusion suggests that self-insertion of the fusion
peptide is not sufficient for HIV-1 Env-mediated fusion.
Self-insertion at high activation of HIV-1 Env may represent
inactivation as was shown for influenza HA [114,115].
There is some evidence, on the other hand, supporting
the insertion of the fusion peptide into the target membrane.
Target cells expressing membrane-anchored T20 are not
susceptible to infection by HIV-1 virions [119], suggesting
that the fusion peptide must be inserted into the target
membrane in order for anti-parallel binding of the T20 to
the N-terminal grooves to occur (Fig. 2). If fusion could
occur solely via self-insertion, which presumably would
create a pre-hairpin structure to form perpendicular to the
membrane, only parallel binding of T20 would be allowed
and therefore, fusion would be rendered insensitive to
inhibition, which is clearly not the case. Similar data on
SIV Env-mediated fusion were obtained using fatty acyl
linked SIV gp41-derived T20 [120]. Therefore, the evidence
favors ‘‘pull’’ models that couple the energy of coil–coil
formation to the movement of the target membrane towards
the viral membrane (see Fig. 2) rather than ‘‘push’’ models
that couple this energy to the bulging of viral membranes as
a result of fusion peptide self-insertion [121]. Mittal and
Bentz discuss a variation of the latter model in a separate
chapter of this volume.
Whatever mechanism drives the process forward, the
essential role of fusion catalysts is to accelerate the rate of
fusion, i.e. lower the activation energy for fusion. The
destabilization of the lipid bilayer as a result of the interac-
tion of segments of fusion proteins with membranes pro-
vides a way to lower these barriers. There have been many
studies showing that synthetic peptides, which promote
liposome fusion, are capable of destabilizing membranebilayers [122]. One motif for destabilizing membranes that
appears to be common to a number of diverse fusion
systems is for the entry of the peptide into the membrane
as an a-helix inserted at an oblique angle [123]. This motif
has been demonstrated by polarized Fourier-transform in-
frared spectroscopy (FTIR) on viral fusion peptides and has
been shown to correlate with the fusogenic activity of the
intact virus [124]. It should be pointed out, however, that
modeling the membrane-inserted fusion peptide as a rigid a-
helix is likely to be an oversimplification. Han et al. [125]
showed that the fusion peptide of influenza virus inserts into
a membrane in a distorted helix with a kinked structure. A
combination of 13C-enhanced FTIR with molecular simu-
lations has been used to study the secondary conformation
of synthetic HIV-1 gp41 fusion peptide in aqueous, struc-
ture-promoting, lipid and biomembrane environments [126].
These studies indicate that at low peptide loading in human
erythrocyte ghosts membranes, the central core of the fusion
peptide (residues 5–15) assumed a-helical conformations.
On the other hand, at high peptide loading, the central core
of the fusion peptide assumed an antiparallel h-structure. It
is tempting to speculate that the a-helical conformations at
low peptide loading are associated with fusion and that the h
structures at high peptide loading are associated with
leakage. This is consistent with the observations by Haque
and Lentz [127] that at low peptide/lipid ratios ( < 1:200),
the gp41 fusion peptide enhances poly(ethylene glycol)-
mediated fusion of highly curved small unilamellar vesicles,
whereas at higher peptide/lipid ratios, the peptide induces
rupture of the vesicles. The insertion of the peptide into the
outer monolayer of the membrane presumably results in a
rapid expansion of the area of the outer monolayer
[128,129]. The bending stress of the outer monolayer may
be relieved by rapid flip-flop of phospholipid [130] and
peptide from outer to inner monolayer followed by the
formation of nanometer-scale pores.5. Fusion pore development
In Fig. 1, the fusion step has been depicted as a question
mark since there is little information regarding this process
in the case of HIV/SIV fusion. The concepts as to what
happens at this juncture are based on the ‘‘stalk-pore’’
paradigm [131–135] (for a recent review, see Ref. [136]).
According to this concept, lipid rearrangements during the
fusion reaction proceed in at least two stages during fusion
[132]. In the first, the contacting monolayer (referred to as
‘‘cis’’) leaflets have merged, but the distal (denoted ‘‘trans’’)
leaflets have remained intact. The structures of these inter-
mediates have been described as ‘‘stalks’’ that further evolve
to form a hemifusion diaphragm. The transmonolayers
making up the hemifusion diaphragm then rupture to form
the complete fusion pore [133].
The stalk-pore paradigm is supported by a large body of
evidence showing that fusion is facilitated by the presence
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negative monolayer curvature propensity, and by lipids in
the trans monolayer that have large intrinsic positive mono-
layer curvature propensity [137]. Conversely, fusion is
inhibited by the presence of lipids in the cis monolayer that
have positive curvature propensity and by lipids in the trans
monolayer that have large intrinsic negative monolayer
curvature propensity. In the case of HA-mediated fusion,
it has been shown that addition to the cis monolayer of
compounds that promote positive curvature (e.g. lysophos-
phatidylcholine) inhibit fusion, and that addition of com-
pounds that promote negative curvature (e.g. oleic acid)
facilitate fusion [138]. To complete the fusion process, the
trans-monolayer has to assume positive curvature. Evidence
for this requirement has been established by showing that
fusion pore formation is promoted by adding chlorproma-
zine [139] or lysophosphatidylcholine [140] to the trans
monolayer side.
This concept was further supported by the observation of
stable lipid mixing intermediates induced by the glycosyl-
phosphatidylinositol-linked ectodomain of HA, GPI-HA,
lacking its transmembrane domain and cytoplasmic tail
[141]. HAwith truncations in its 27-amino acid TM domain
[142] or with certain replacements of the fusion peptide
[143,144] also display the hemifusion phenotype. Hemi-
fusion phenotypes have also been observed with truncated
[145] or GPI-anchored [146] paramyxovirus Env glycopro-
teins. Furthermore, substitution of two glycine residues in
the TM domain of VSV Env by Ala or Leu resulted in a
hemifusion phenotype [147].
The hypothesis is thus widely held that hemifusion is a
key intermediate stage of membrane fusion [148]. Howev-
er, a recent attempt to visualize the fine structure of the
contact area between GPI-HA-expressing cells and RBC
using transmission electron microscopy to image thin
sections of rapidly frozen, freeze-substituted material did
not reveal any such diaphragms with the limits of detection
(70–100 nm) [149]. Presumably, diaphragms need to be
about an order of magnitude larger in order to be revealed
by transmission electron microscopy. However, a multi-
plicity of small fusion sites was observed within which
either lipid redistribution or formation of non-enlarging
fusion pores could ensue [150]. These contact sites appear
in the form of dimples on both membranes. Such dimpling,
which has previously been observed in the process of
exocytosis in mast cells [151], has been put forward as
an early step in the fusion reaction [152–156]. Frolov et al.
[149] observed these dimples in both GPI–HA and HA,
indicating that the transmembrane domain may not be
essential for contact site formation. However, agents that
increase the positive curvature of inner monolayers pro-
mote fusion pore expansion in the GPI–HA hemifusion
intermediate [139]. Therefore, it seems likely that the TM
domain of intact viral envelope glycoproteins promotes
fusion pore expansion by perturbing the inner monolayers
of the fusing membranes.The stalk-pore hypothesis is supported in the case of HIV
Env-mediated fusion by experiments showing that addition
of lysophosphatidylcholine to the cis monolayer inhibited
fusion [31]. However, other experiments indicate that lyso-
phosphatidylcholine may affect viral protein–host cell bind-
ing rather than the formation of lipid intermediates required
for fusion [157]. Although a number of mutations of fusion
proteins from several different viruses have been shown to
result in lipid dye spread without mixing of aqueous dye
when the mutant proteins were expressed on cell surfaces,
no mutants of HIV, SIV, Mo-MuLV Env created so far has
been shown to produce hemifusion. GPI-anchored HIV-1
expressed in cells was incapable of mediating membrane
fusion either by lipid or contents mixing [41]. Similarly,
membrane anchor truncation mutants of Mo-MuLV [158] or
SIV Env [158a] did not induce lipid or contents mixing. It is
possible that the differences may be due to the fact that in
the case of ortho and paramyxo viruses, red blood cells were
used as targets whose membranes may stabilize the inter-
mediate.
In general, no differences are observed in the kinetics of
redistribution of lipid dyes versus small aqueous markers as
a result of HIV-1 Env-mediated cell fusion [31,42]. How-
ever, in the presence of the C-terminal peptide T20 [106],
different patterns of inhibition were seen when fusion was
monitored by lipid versus aqueous dye redistribution
[42,43], although not all observations are consistent with
each other [31]. These differences may reflect different
sensitivities of the assay to lipid and contents mixing,
especially when the efficiency of pore formation is largely
reduced when six-helix bundle formation is impaired.
Although the energy of interaction of the coiled coil is
clearly important in the creation of a fusion pore [31], it is
not the only consideration. In order to examine the role of
regions outside the six-helix bundle, mutations were intro-
duced into HIV-1 gp41 within a region immediately adja-
cent to the membrane-spanning domain. This region, which
is predicted to form an a-helix, contains highly conserved
hydrophobic residues and is unusually rich in tryptophan
residues. In addition, this domain overlaps the epitope of a
neutralizing monoclonal antibody, 2F5, as well as the
sequence corresponding to a peptide, DP-178, shown to
potently neutralize virus. Some mutations did not affect
HIV-1 Env-mediated fusion whereas other rendered HIV-1
Env incapable of mediating fusion. However, two mutations
in this region display a distinct phenotype that is restricted
in fusion pore enlargement [159]. Presumably, the hinge
region between the TM anchor and the six-helix bundle
needs to be flexible enough to allow the viral and target
membranes to be pulled together to closer proximity. The
optimal effect will be achieved when the six-helix bundle is
parallel with the plane of the membrane (Fig. 1). Removal
of the hinge region totally abrogates this effect. However, a
few gp41 hinge mutants are weakened in their ability to tilt
the six-helix bundle. Therefore, the intermediate (parallel)
structure will not be present for a sufficient amount of time
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non-enlarging pore (NEP) phenotype. This phenotype has
also been seen with SIV Env trans-membrane anchor
truncation mutants [158a].
The data regarding the NEP phenotype in the absence of
hemifusion, taken together with intermediates revealed by
immunostaining and susceptibility to C-terminal inhibitors
(see Sections 4.1 and 4.2) suggest the model shown in Fig.
2. Since the fusion sites are presumably on microvilli [67]
that are naturally curved, the Env does not have to take care
of this aspect of the fusion process. Insertion of the fusion
peptide into the target membrane and formation of coil–coil
provide the energy for moving the membranes in close
proximity from which fusion can ensue. The tension created
by binding of the C-terminal regions into the N-terminal
grooves provides the driving force needed to pull viral and
target membranes together. In the pre-fusion state, two of
the three C-terminal helices are incorporated into the core
bundle of three N-terminal helices. Having the third C-
terminal helix ‘‘unzipped’’ allows for the binding of mimetic
peptides to the bundle, which are known to inhibit the fusion
mechanism beyond this stage. This situation may account
for apparently contradictory data that gp41 is still sensitive
to T20 [31] at a stage where six-helix bundles are detected
by immunofluorescence [38]. The oblique angle of the
fusion peptides destabilize the outer, apposed layer of the
target cell membrane [160]. The close apposition in the pre-
fusion state in the presence of T20 may allow the exchange
of lipids [42,43]. However, once a fusion pore is formed
(Fig. 2B), it rapidly expands leaving no time for observation
of hemifusion [31]. Mutations in the hinge region [159] or





Fig. 3. Revised model of HIV-envelope-mediated membrane fusion. The first step
gp120 or gp120bd), which can be blocked by sCD4, antibodies against the CD4 bi
small molecules (see Ref. [167] for a review). Secondly, the gp120/gp41 compl
exposed co-receptor binding site, and gp41php, pre-hairpin gp41), which allow fusio
co-receptors (CoR) are co-localized with CD4 molecules in lipid rafts composed of
lowering the temperature, cytochalasin, MhCD, and GSL biosynthesis inhibitors
envelope, which is blocked by antibodies against the gp120 binding site on the co
receptors agonists and antagonists [167]. Gp120 and gp41 then dissociate and the
receptor engagement [48]. This is also presumed to be the point at which the fusi
through the oligomerization of several (n) trimers, is pore expansion, which is imstable intermediates that give rise to transient pores. Only
robust interactions of these crucial domains of the fusion
proteins with the lipid membranes will ensure the comple-
tion of the reaction.
The multimerization and/or inter-envelope interaction of
multiple trimers may be necessary to create a fusion pore.
Considerable evidence has been found to support this hy-
pothesis in the case of influenza HA. From the kinetics of
dye transfer of cell–cell fusion pairs, a fusion pore has been
estimated to have at least six HA trimers [161]. Analysis of
pore conductivity data has yielded a value of three trimers
necessary for fusion [162]. A similar estimation has been
found from data involving cell fusion kinetics, measuring
time lag versus envelope density [163]. Still other theoretical
calculations posit that only a few trimers are needed to create
the initial pore, and then multiple proteins outside the contact
area are recruited for pore enlargement [164]. In contrast to
these studies are reconstitution experiments that claim the
lack of cooperativity [165], although this discrepancy may
be due to strain differences.
In the case of HIV Env-mediated fusion, not much
evidence is available regarding the multiplicity of Envs
required for fusion pore formation. Self-aggregation of C-
terminal peptides of the HR2 region of gp41 has been
observed in liposome membranes [43]. These data have
been interpreted in terms of a model, which is discussed by
Shai in a separate article in this volume. According to this
model, lipid membranes induce conformational changes in
the six-helix bundle, which enable association of gp41
molecules leading to fusion pore formation. In another
study, Freed et al. [117] have shown that the V2E mutant
in the fusion peptide of gp41 results in an abrogation ofis the initial binding and engagement with CD4 receptor (resulting in bound
nding site on gp120, antibodies against the gp120 binding site on CD4, and
ex undergoes conformational changes (represented as gp120cr, gp120 with
n to become sensitive to C-terminal peptides like T20 [34]. In the third step,
cholesterol (Chol) and glycosphingolipids (GSL), which can be blocked by
[18,67,168]. The fourth step is the engagement of the co-receptor by the
-receptor, antibodies against the co-receptor binding site on gp120, and co-
six-helix bundle configuration (gp41hp) is formed concomitantly with co-
on peptide is inserted in to the target and/or host membrane. The final step,
paired in gp41 NEP mutants (see text).
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expressed with excess wild-type envelope. This effect was
not seen when the mutant was co-expressed with HIV-2,
suggesting specific interactions between multiple trimers are
necessary for fusion. However, a threshold number of
molecules have not yet been determined, although envelope
density has clearly been shown to affect the fusion yield
[44]. Due to the requirement of multiple CD4 and co-
receptor molecules for fusion [52,53] and that the stoichi-
ometry of trimer to CD4 molecule is 1:1 [166], it is
reasonable to assume that multiple proteins are required
for fusion pore formation.6. Concluding remarks
The recent high-resolution determination of the structure
of the gp41 core from HIV-1 provides well-defined land-
marks in the terrain the viral envelope glycoproteins
navigate following CD4 and co-receptor-induced confor-
mational changes (Figs. 1 and 2). Further elucidation has
been accomplished through the combined data covered in
this review, resulting in a revision of the Chan/Kim model.
The current HIV Env-mediated fusion reaction scheme we
have is summarized in Fig. 3. The process leading to six-
helix bundle formation has been split into CD4 and co-
receptor dependent steps. In addition, we have supple-
mented it with the steps of co-receptor recruitment and
oligomerization as well as pore enlargement. A number of
steps in the fusion cascade are revealed by inhibitory
conditions that block fusion at this step. The first step is
the initial binding and engagement with CD4 receptor,
which can be blocked by Leu3a antibody. The gp120/
gp41 complex then undergoes conformational changes,
allowing for the N-terminal heptad repeat region of gp41
to be exposed, sensitizing fusion to C-terminal peptide
inhibition at this second step. This conformational change
in gp41 is now defined as the pre-hairpin formation.
Thirdly, co-receptors are recruited to the binding site,
presumably into rafts rich in cholesterol and glycosphingo-
lipids. Self-aggregation and/or interaction of several enve-
lope/CD4 complexes may also occur at this step. This is
blocked by cytochalasin and temperature, which may
inhibit actin polymerization, or by MhCD, which inhibits
raft formation. The fourth step is the engagement of the co-
receptor, which is inhibitable by co-receptor agonists and
antagonists. Concomitant with co-receptor engagement,
gp120 and gp41 dissociate and the six-helix bundle con-
figuration is formed, desensitizing fusion to C-terminal
peptide inhibition. This is also presumed to be the point
at which the fusion peptide is inserted in to the target and/or
host membrane, leading to the establishment of a fusion
pore. The final step is pore expansion, which is impaired by
gp41 hinge and transmembrane mutations. Several critical
areas in this model are in need of much additional data, for
instance, fusion peptide insertion, oligomerization, and poreexpansion. These uncertainties underscore the incomplete-
ness of any present model of HIV entry without further
studies. Many models based on current structural data,
which includes neither fusion peptides and transmembrane
anchors nor regions between those domains and six-helix
bundles (Fig. 1), fail to give enough importance to regions
which are crucial for fusion activity. Mutagenesis of these
undetermined domains combined with sensitive assays for
the activity of the modified proteins will lead to refinement
of our thinking about the HIV-1 Env-mediated fusion
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